Collegium Pharmaceutical Inc
NASDAQ:COLL
Collegium Pharmaceutical Inc
NASDAQ:COLL
Price:
45.33
USD
-3.04%
Market Closed
Market Cap:
$1.4B
Relative Value
The Relative Value of one
COLL
stock under the Base Case scenario is
56.27
USD.
Compared to the current market price of 45.33 USD,
Collegium Pharmaceutical Inc
is
Undervalued by 19%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
COLL
Relative Value
Base Case
56.27
USD
Undervaluation 19%
Multiples Across Competitors
COLL Competitors Multiples
Collegium Pharmaceutical Inc Competitors
Collegium Pharmaceutical Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Collegium Pharmaceutical Inc
NASDAQ:COLL
|
1.4B USD | 1.9 | 24.8 | 5 | 12.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
960.1B USD | 14.7 | 46.5 | 31.4 | 33.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579.4B USD | 6.2 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
281.2B CHF | 4.6 | 29.9 | 12.6 | 14.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
228.3B GBP | 5.5 | 33.7 | 16 | 23.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
235.6B CHF | 5.4 | 21.7 | 13.4 | 17.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.4B USD | 4.5 | 16.2 | 10.1 | 11.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.4 | 13.2 | 9.7 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158B USD | 2.5 | 20.3 | 7.5 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.2B USD | 2.5 | 17.3 | 6.8 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
